Testosterone-Lowering Therapy for Prostate Cancer May Increase Alzheimer's Risk

Men taking androgen deprivation therapy (ADT) for prostate cancer were almost twice as likely to be diagnosed with Alzheimer’s disease in the years that followed than those who didn’t undergo the therapy, an analysis of medical records from two large hospital systems by Penn Medicine and Stanford University researchers has shown.

Steve Graff

Testosterone-Lowering Therapy for Prostate Cancer May Increase Alzheimer's Risk

Men taking androgen deprivation therapy (ADT) for prostate cancer were almost twice as likely to be diagnosed with Alzheimer’s disease in the years that followed than those who didn’t undergo the therapy, an analysis of medical records from two large hospital systems by Penn Medicine and Stanford University researchers has shown.

Steve Graff

Penn Team Pinpoints Immune Changes in Blood of Melanoma Patients on PD-1 Drugs That Put Potential Biomarker within Reach

A simple blood test can detect early markers of “reinvigorated” T cells and track immune responses in metastatic melanoma patients after initial treatment with the anti-PD-1 drug pembrolizumab, researchers from the Abramson Cancer Center of the University of Pennsylvania report in new research being presented at the inaugural CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference.

Steve Graff

Multiple Myeloma Patients More Vulnerable to 'Financial Toxicity' Due to Expensive, Longer Courses of Treatments, Penn Study Finds

Even patients with health insurance who have multiple myeloma may be vulnerable to “financial toxicity” – including those who make over $100,000 a year – because of the higher use of novel therapeutics and extended duration of myeloma treatment, researchers from Penn’s Abramson Cancer Center report in this week’s 

Steve Graff

Attitudes about Complementary and Alternative Medicine Predict Use Among Cancer Patients, Penn's Abramson Cancer Center Finds

A cancer patient’s expectations about the benefits of complementary and alternative (CAM) and their perceived access to CAM therapies are likely to guide whether or not they will use those options, according to a new study published ahead of print in the journal CANCER from researchers at Abramson Cancer Center of the University of Pennsylvania. 

Steve Graff

Penn Scientists Receive Grant for Neuroendocrine Cancer Immunotherapy Research

Researchers from the Perelman School of Medicine at the University of Pennsylvania received a $400,000 grant from the Caring for Carcinoid Foundation (CFCF), a non-profit that funds research for carcinoid, pancreatic, and related neuroendocrine cancers (NETS), to investigate the use of an experimental gene therapy that engineers immune cells to attack cancers.

Steve Graff